335 results about "Control drugs" patented technology

The present invention relates to a molecular sustained controlled release system constructed by the conjugation of molecules to be released with biodegradable polyester polymer via covalent bond and method for preparation thereof. In accordance with the present invention, the system may be formulated into microspheres, nanoparticles, or films. The molecular release rate from the above system can be regulated to be proportional to the chemical degradation rate of the biodegradable polyester polymers, resulting in near zero order kinetics profile of release without showing a burst effect, Moreover, a high loading efficiency of hydrophilic drugs can be achieved.

Implantable devices and methods for use in the treatment of osteonecrosisare provided. The device includes at least one implant device body adapted for insertion into one or more channels or voids in bone tissue; a plurality of discrete reservoirs, which may preferably be microreservoirs, located in the surface of the at least one implant device body; and at least one release system disposed in one or more of the plurality of reservoirs, wherein the release system includes at least one drug selected from the group consisting of bone growth promoters, angiogenesis promoters, analgesics, anesthetics, antibiotics, and combinations thereof. The device body may be formed of a bone graft material, a polymer, a metal, a ceramic, or a combination thereof. The device body may be a monolithic structure, such as one having a cylindrical shape, or it may be in the form of multiple units, such as a plurality of beads.

An implantable, refillable, rate controlled drug delivery device is disclosed that includes a base structure having at least a first opening and a second opening, the base structure defining a chamber, a septum covering the first opening and configured to substantially prevent leakage from the first opening to an exterior of the device, a drug delivery tube comprising a first and second distal end, wherein the first distal end of the tube communicates with the chamber through the second opening, and at least one rate-limiting permeable membrane disposed across a passage between the base structure and the second distal end of the drug delivery tube, which membrane passively regulates drug delivery. The drug delivery device is used to provide controlled drug delivery to an internal portion of the body and is advantageously leak-proof and does not rely on a pressure differential to drive the drug from the device.

The invention pertains to methods and devices for controlling the pharmacokinetics of administered substances, particularly therapeutic substances by combining advantages of delivery to two or more compartments within the skin. The invention provides methods and devices for delivering substances to subcutaneous and intradermal compartments of the skin to achieve a hybrid pharmacokinetic profile that has a portion similar to that achieved by intradermal delivery, e.g., rapid and high peak onset levels of the substance, and a portion similar to that achieved by subcutaneous delivery, e.g., longer circulating levels of the substance.

A transdermal delivery system is provided for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric and/or adhesive coating that is applied to either the transdermal system's backing or release liner. The transdermal delivery device is manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile.

The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

A delivery device for patient-controlled infusion of a medicament (6), the delivery device comprising a reservoir (2) for the medicament (6) and a pump (4) having a predetermined delivery dose which is capable of displacing the medicament from the reservoir (2) and delivering it to a patient, wherein the pump (4) comprises a pumping means (14), a first conduit (10), capable of restricting flow rate, chosen in conjunction with the delivery dose of the pumping means (14) to define a predetermined maximum dosage rate, said conduit (10) connecting the reservoir (2) to a pumping means (14), a one-way valve (18) in fluid communication with the first conduit (10) and the pumping means (14) which permits medicament flow into the pumping means (14) but prevents reverse flow, a controlling means (32), and a second conduit (28) extending from the pumping means and having a distal end (30) through which, the medicament may be released, wherein the controlling means (32), (a) is in fluid communication with the pumping means (12) and the second conduit (28); (b) opens when pressure within the dose chamber (12) exceeds a predetermined minimum opening pressure for the controlling means (32); and, (c) is adapted to prevent the reverse flow of medicament and air into the pumping means.

A patient controlled liquid drug administration device comprises a reciprocating pump having an inlet connectable to a source of a pressurized liquid drug, and an outlet connectable to the patient. A clamp rotates between closed and open positions respectively blocking and enabling pump outflow. A plunger above the pump has an end contacting a movable wall of the pump and is movable between raised and lowered positions. A button above the plunger moves between extended and depressed positions, and has a ledge that engages the clamp when the button is moved to the depressed position and moves the clamp to its open position. A compression spring is disposed between the plunger and the button. A spring catch engages a detent in the button when the button is moved to its depressed position and holds the button there until released by a catch release on the plunger that disengages the spring catch from the detent in the button when the plunger is moved to its lowered position. A removable tab permits easy, rapid priming of the pump by holding the clamp in its open position regardless of the position of the button, and by holding the button in its depressed position regardless of the position of the plunger.

A secure electronic procurement system allows a user (e.g. pharmacist) to order and confirm receipt electronically over a network (e.g. Internet) goods normally subject to a verifiable chain of custody (e.g. narcotics, controlled drugs and substances, other public distribution regulated goods or valuables). The system includes hardware and software for a user device, a secure procurement system, a supplier system and a certificate authority to authenticate communications, particularly user orders and confirmed receipts. The supplier system may be a legacy EDI based order system. Copies of electronic orders, shipping notices and receipts confirming shipment received together with digital signatures are securely stored for audit trail purposes. Business rules within the secure procurement system operate to ensure proper adherence to the chain of custody.

Polymeric nanofibers have been developed which are useful in a variety of medical and other applications, such as filtration devices, medical prostheses, scaffolds for tissue engineering, wound dressings, controlled drug delivery systems, cosmetic skin masks, and protective clothing. These can be formed of any of a variety of different polymers, both non-biodegradable or biodegradable, and derived from synthetic or natural sources.

The present invention discloses 1) the composition of fibrous articles and 2) methods for using these articles in medical applications.

The biodegradable fibrous articles, which are preferably formed by electrospinning polymer solution of biodegradable fiberizable material with or in conjunction with medicinal agents and bioactive materials, comprise a composite (or asymmetric composite) of nanofibers with actives.

Nanofibrous articles having specific medical uses include controlled drug delivery devices, glaucoma implants, tissue engineering, wound dressings, reinforcement grafts, corneal shields, and orbital blowout or sinus reconstructive materials.

The methods include controlled drug delivery of a medicinal agent and providing treatment for inflammation, infection, trauma, glaucoma, and degenerative diseases.

The drug delivery compositions and methods of this invention are directed towards improving the delivery of drugs to a target area of the body. These drug delivery compositions are nanofiber webs, mats, or whiskers which incorporate an active ingredient for delivery into a bodily fluid. The active ingredient is delivered in a controlled manner by placing the nanofiber web into the bodily fluid which allows the drug embedded in the nanofiber to be released in a controlled and longer lasting manner.

Medical device and methods are provided for controlled drug delivery in a cardiac patient. The device includes an implantable drug delivery module comprising reservoirs containing a drug and a control means for selectively releasing an effective amount of drug from each reservoir; one or more electrodes or sensors for cardiac monitoring, stimulation, or both; and a microcontroller for controlling operational interaction of the drug delivery module and the cardiac electrode. The electrodes may comprise ECG monitoring, cardioversion, or cardiac pacing electrodes. A medical device also is provided for controlled delivery of drug to a patient having congestive heart failure, which includes an implantable drug delivery module comprising a natriuretic peptide and a release mechanism for selectively releasing a pharmaceutically effective amount of the natriuretic peptide into the patient; and a microcontroller for controlling the release mechanism, for example, in response to one or more monitored patient parameters.

The present invention relates to a controlled drug release system in which a certain ratio or retinoic acid is incorporated into a microsphere comprising biodegradable polymer and amphoteric block copolymer having both hydrophilic and hydrophobic groups.

Disclosed is a surfacely modified hydrophobic Chitosan oligosaccharide polymer drug-loaded colloidal cluster, obtained by grafting chitosan with a average molecular weight of 1.5kD-51kD and aliphatic acid of C10-C22, comprising based on hydrophobic modified Chitosan oligosaccharide polimer colloidal clusters, modifying amidogens or hydroxy groups of Chitosan oligosaccharide molecules on polimer surface with bi-functional small organic moleculers, forming chemical bond bridges between molecules on the surfaces of polymer colloidal clusters,to improve the instability of polymer colloidal cluster diluted, and to imorove the original loose structure of polimer colloidal cluster surfece to form a fine and close net-shaped structure, to decrease a sudden release of drugs, and to control drugs with slow release. The drug-loaded colloidal cluster provided is a nano-carrier with excellent organelle targeting, is applicated in life science field and pharmacy field.

A drug package comprising a plurality of drug vials containing drugs for delivery to a patient in a drug delivery device; and a data carrier including drug treatment information for use by the drug delivery apparatus.

Controlled-drug-delivery oral devices are implanted or inserted into an oral cavity, built onto a prosthetic tooth crown, a denture plate, braces, a dental implant, or the like. The devices are refilled or replaced as needed. The controlled drug delivery may be passive, based on a dosage form, or electro-mechanically controlled, for a high-precision, intelligent, drug delivery. Additionally, the controlled delivery may be any one of the following: delivery in accordance with a preprogrammed regimen, delivery at a controlled rate, delayed delivery, pulsatile delivery, chronotherapeutic delivery, closed-loop delivery, responsive to a sensor's input, delivery on demand from a personal extracorporeal system, delivery regimen specified by a personal extracorporeal system, delivery on demand from a monitoring center, via a personal extracorporeal system, and delivery regimen specified by a monitoring center, via a personal extracorporeal system. Drug absorption in the oral cavity may be assisted or induced by a transport mechanism, such as any one of, or a combination of iontophoresis, electroosmosis, electrophoresis, electroporation, sonophoresis, and ablation. The oral devices require refilling or replacement at relatively long intervals of weeks or months, maintain a desired dosage level in the oral cavity, hence in the gastrointestinal tract, for extended periods, address situations of narrow drug therapeutic indices, and by being automatic, ensure adherence to a prescribed medication regimen. The oral devices and methods for controlled drug delivery apply to humans and animals.

Self-polymerization of mono-aziridine (or azetidine) and multi-aziridine (or azetidine) containing compounds with vinyl group containing organic acid, such as acrylic acid (AA), 2-methylenesuccinic acid, 2,3-dimethylenesuccinic acid and etc, at ambient temperature results in the new type of cross-linked and linear type copolymers, respectively.

The polymerization of multi-functional aziridine (or azetidine) containing compounds with vinyl group containing organic acid results in the formation of high cross-linked polymers. The self-polymerization takes place at ambient temperature and the resultants, cross-linked polymeric networked materials, are solvent insoluble and potential for adhesive, composite matrix and other applications. These insoluble materials are hydrolyzed in an acidic or basic condition to form the water soluble β-amino acids.

A linear poly(β-aminoester) is obtained from the self-polymerization of vinyl group containing organic acid with mono-aziridine (or azetidine) containing compound at ambient temperature. poly(β-aminoester) is applicable for gene transfer, controlled drug release and other applications. This self-polymerization process offers a convenient route for preparing poly(β-aminoesters).

The present invention relates to a conjugate of hydrophilic polymer-multicarboxyl oligopeptide and drug molecule of the following formula:

wherein: P is a water soluble polymer; m is an integer of 2˜12; j is an integer of 1˜6; R_i is a group selected from H, C_1-12 alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl; X and Z are linking groups; and TA is drug molecule. The conjugate has low toxicity and an ability to carry more than one drug molecule to improve solubility, sustain and control drug release, and has a remarkably enhancing effect especially to antitumor drug such as paclitaxel and camptothecin etc.

The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a matrix within the controlled drug delivery device). The drug formulation comprises an amount of drug sufficient for treatment and is stable at body temperatures (i.e. no unacceptable degradation) for the entire pre-selected treatment period. The drug delivery devices store the drug formulation safely (e.g., without dose dumping), provide sufficient protection from bodily processes to prevent unacceptable degradation of the formulation, and release the drug formulation in a controlled fashion at a therapeutically effective rate to treat pain. In use, the drug delivery device is implanted in the subject's body at an implantation site, and the drug formulation is released from the drug delivery device to a delivery site. The delivery site may be the same as, near, or distant from the implantation site. Once released at the delivery site, the drug formulation enters the systemic circulation and is transported to the site of action in the body to modulate the pain response (e.g., the brain or other pain sensory location).